Publikationen in Zusammenarbeit mit Forschern von Universidad de Cantabria (41)

2024

  1. Guidelines for minimal information on cellular senescence experimentation in vivo

    Cell, Vol. 187, Núm. 16, pp. 4150-4175

  2. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  3. The impact of genetic variations in the serotonergic system on symptom severity and clinical outcome in functional neurological disorders

    Journal of Psychosomatic Research, Vol. 186

  4. Worldwide distribution of genetic factors related to severity of COVID-19 infection

    Annals of Human Biology, Vol. 51, Núm. 1

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum: Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (Nature (2023) 617 7962 (764-768))

    Nature

  3. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

    Nature, Vol. 617, Núm. 7962, pp. 764-768

  4. HLA-A*11:01 and HLA-C*04:01 are associated with severe COVID-19

    HLA, Vol. 102, Núm. 6, pp. 731-739

  5. Psychiatric polygenic risk as a predictor of COVID-19 risk and severity: insight into the genetic overlap between schizophrenia and COVID-19

    Translational Psychiatry, Vol. 13, Núm. 1

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  2. Severity of COVID-19 attributable to obesity according to BMI and CUN-BAE

    Semergen, Vol. 48, Núm. 8, pp. 6

  3. pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation

    Nature Communications, Vol. 13, Núm. 1

2020

  1. Levels of the novel endogenous antagonist of ghrelin receptor, liver-enriched antimicrobial peptide-2, in patients with rheumatoid arthritis

    Nutrients, Vol. 12, Núm. 4

  2. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  3. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

2019

  1. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  2. TGFβ2-induced senescence during early inner ear development

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2017

  1. Analysis of the R1b-DF27 haplogroup shows that a large fraction of Iberian Y-chromosome lineages originated recently in situ

    Scientific Reports, Vol. 7, Núm. 1